|
|
|
|
Transcode Therapeutics Inc (NASDAQ: RNAZ) |
|
|
|
| |
RNAZ $7.6100
$0.0500 
0.66%
|
Volume (M):
14
Open :
7.63 52 Wk Avg :
272.37
|
RNAZ $7.6100
$0.0500
0.66%
|
Volume (M):
14
Open :
7.63 52 Wk Avg :
272.37
|
|
Transcode Therapeutics Inc RNAZ.NASDAQ Chart and Quote
|
RNAZ Today's High:
|
$7.87
|
RNAZ Shares One Week Perf:
|
5.4 %
|
| RNAZ Today's Low: |
$ 7.52 |
RNAZ Shares 30 Day Performance: |
-23.91 % |
| Number of RNAZ Shares Traded (M): |
14 |
RNAZ Share Price 52 Wk High: |
$ 1,182.72 |
| Value of RNAZ's Shares Traded (M$): |
$ 108 |
RNAZ Share Price 52 Wk Avg: |
$272.37 |
| Share Price at the Open: |
$7.63 |
RNAZ's Share Price 52 Wk Low: |
$6.15 |
During the past 5 days Transcode Therapeutics Inc stock went down by % , this brings the share price to -49.75% during the Q2 of 2025. Transcode Therapeutics Inc stock trades only 23.7% above its 52 week low.
Transcode Therapeutics Inc 's share price is delayed for 15 minutes
Select the Period on the chart to see the RNAZ.NASDAQ's share price performance, or type custom period of your choice
RNAZ Company Profile >> Share performance within Major Pharmaceutical Preparations Industry >> Compare RNAZ to its Benchmarks |
News about Transcode Therapeutics Inc's Stock Splits and Dividends |
|
July 24, 2024
TransCode Therapeutics Continues to Secure Funding for Innovative RNA Oncology Treatments: Impact on Shareholders and Financials
In recent news, TransCode Therapeutics, a clinical-stage RNA oncology company, has made significant strides in securing funding for their innovative treatments. With a series of successful financial offerings, including a $1.2 million registered direct offering of common stock in November 2023 and an $8.5 million public offering in September 2023, the company has demonstrated a strong commitment to advancing their mission of more effectively treating cancer using RNA therapeutics.
The most recent announcement, which revealed that TransCode Therapeutics now has 5.142398 million shares outstanding and a current price of $0.3035, showcases the impact that these financial initiatives have had on the company s overall financial position. By securing additional funds through these offerings, TransCode Therapeutics has bolstered their ability to further research and develop their innovative RNA oncology treatments, ultimately benefiting both shareholders and patients alike.
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
